TruScreen Ltd
(ASX:TRU) Share Price and News

Overview of TruScreen

TruScreen Group (ASX:TRU), based in New Zealand and listed on the ASX, is a pioneering medical device company revolutioniding cervical cancer screening. Founded in 2013, the company has rapidly expanded its global presence, with its innovative TruScreen Cervical Cancer Screening System leading the way in accessible and accurate diagnostics.

The company’s TRU system is designed to detect the presence of pre-cancerous and cancerous tissues in the cervix, by low level electrical and optic signals. It consists of a handheld device (HHD), intelligent cradle and a single-use-sensor (SUS). The device has an expected life of 5–7 years, but the SUS is used once per test per patient in order to avoid cross-infection.

The HHD collects and analyses the data and provides instant results, enabling clinicians/physicians to immediately plan appropriate patient care. It needs no tissue samples from the cervix, nor high-quality laboratory infrastructure to process and analyse the results.

TRU has wide application in Low and Middle-Income Countries (LMICs) where women typically lack access to cervical cancer screening. This real-time, single-visit and mobile screening technology does not require any high-cost lab infrastructure and can be conducted by a nurse or trained person based on local healthcare rules.

History of TruScreen

TruScreen's journey began in 2013, driven by Dr. Catherine MacDiarmid's research and a mission to improve cervical cancer screening globally. The company quickly moved from concept to clinical trials, receiving New Zealand regulatory approval in 2017.

By 2019, TruScreen was publicly listed, raising capital for expansion and further research. The subsequent years saw the company solidify its presence in multiple international markets, gaining recognition for its innovative approach to cervical cancer prevention.

In FY2025 TruScreen expanded its product distribution, re-entered India with a new distributor, and launched a five-year screening program in Ho Chi Minh City targeting 260,000 women, signalling traction in key Asian markets. The company also signed a strategic Memorandum of Understanding with Hangzhou Dalton Bioscience to expand product offerings and channel reach.

Future Outlook of TruScreen (ASX:TRU)

TruScreen's future looks promising with significant growth in China and expansion into new markets like Saudi Arabia and Zimbabwe. The recognition of their technology in important medical guidelines and the success in clinical evaluations suggest a strong potential for widespread adoption.

The company’s real-time, lab-independent solution is well-aligned with public health initiatives in low- and middle-income regions, and multiple national guideline inclusions — including WHO and emerging markets — may help drive long-term demand.

Ongoing regulatory approvals, partnerships and screening programs could accelerate revenue as device installations and consumable use scale. Continuing clinical validation, such as recent studies confirming use in pregnant women, also supports broader utility.

Investment Potential of TruScreen

TruScreen is fundamentally a speculative, early-stage medical technology investment. The growth case is supported by a large global addressable market — with over a billion women of screening age — and supportive public health policies targeting increased cervical cancer screening coverage.

Its AI-driven platform positions it ahead of some legacy technologies for real-time screening. However, the company has historically operated at a loss and requires continual investment in commercial expansion, regulatory compliance and market development, meaning earnings remain distant.

Investing in TRU may appeal to investors comfortable with high risk and long time horizons who believe in adoption across emerging markets and further clinical validation. More conservative investors seeking stable revenue and profits may find the stock’s early-stage characteristics and limited earnings less appealing.